Back to results
US 11,530,401 B2Granted
Short-acting Factor VII polypeptides
AssigneeCoagulant Therapeutics Corporation
InventorsMaxine Bauzon, Terry Hermiston
Life of this patent
Estimating the term…
Abstract
Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.
Claims22
An isolated variant Factor VII polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 16 and comprising mutation(s) in the Gla domain that increase the variant Factor VII polypeptide affinity for activated platelets, wherein the variant Factor VII polypeptide comprises N-linked glycosylation sites of wild-type human Factor VII at amino acid residues 145 and 322 with reference to SEQ ID NO:
- 16 and further wherein the variant Factor VII polypeptide has a ratio of moles of conjugated sialic acid to moles of N-linked glycan between 0 and 2.0.
An isolated variant Factor VII polypeptide comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 16 and comprising mutation(s) that result in increased Factor VII polypeptide affinity for activated platelets, wherein the variant Factor VII polypeptide comprises N-linked glycosylation sites of wild-type human Factor VII at amino acid residues 145 and 322 with reference to SEQ ID NO:
- 16 and further wherein the variant Factor VII polypeptide has a ratio of moles of conjugated sialic acid to moles of N-linked glycan between 0 and 2.0.
Dependencies are inferred from the claim text.